TD5A Stock Chart & Stats
€17.00
-€0.16(-0.45%)
At close: 4:00 PM EST
€17.00
-€0.16(-0.45%)
Day’s Range― - ―
52-Week Range€8.79 - €23.09
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€924.88M
Enterprise Value€1.61B
Total Cash (Recent Filing)€570.26M
Total Debt (Recent Filing)€734.74M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding68,529,090
10 Day Avg. Volume34
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.77Price Target Upside57.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.61
Revenue Forecast (FY)€938.60M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth / Installed BaseSustained triple‑digit TTM revenue growth implies accelerating adoption of Tandem pumps and related consumables. A growing installed base increases recurring consumable demand and creates a durable revenue flywheel, supporting multi‑period top‑line visibility independent of short‑term market moves.
Improving Gross MarginsMargin expansion to mid‑50s reflects better product economics and favorable mix, suggesting scalable manufacturing and pricing power. Higher gross margins provide structural support for reaching operating profitability as revenue scales, enhancing long‑term margin sustainability even with continued R&D and commercial investment.
Stronger Cash Position And FinancingA large cash balance and a 0% interest convertible financing materially extend the company’s runway, enabling continued product development, international go‑direct expansion, and supply investments. This improved liquidity reduces near‑term refinancing risk and supports strategic execution over the coming quarters.
Bears Say
Elevated Leverage / Thin EquityA debt‑heavy capital structure with a markedly thinner equity cushion increases financial vulnerability to operating setbacks. High leverage limits flexibility for M&A or cushioning against supplier/market disruptions, raises refinancing and covenant risk, and can force dilutive or costly financing if performance softens.
Ongoing Net LossesPersistent operating and net losses mean the company has not yet converted growth and margin gains into sustainable profitability. Continued losses can pressure free cash flow and necessitate external financing for strategic initiatives, making long‑term value creation contingent on consistent path to positive EPS and FCF.
Operational / Supply Execution RisksSupplier capacity constraints and the complex PayGo pharmacy rollout introduce structural execution risk: disrupted consumable availability and slower channel conversion can dent recurring revenue and complicate physician/patient workflows. These operational frictions can persist and hinder installed‑base monetization.
TD5A FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was €8.79 and its highest was €23.09 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is €924.88M.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 06, 2026 which is in 25 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 07, 2026. The company reported -€0.261 earnings per share for the quarter, beating the consensus estimate of -€0.389 by €0.128.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.29.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 68,529,090 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -€0.261 in its last earnings report, beating expectations of -€0.389. Following the earnings report the stock price went down -9.804%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in DE:TD5A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€26.77 (57.47% Upside)
€26.77 (57.47% Upside)
Blogger Sentiment
Bullish
DE:TD5A Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.70%
12-Months-Change
Fundamentals
Return on Equity
-68.29%
Trailing 12-Months
Asset Growth
25.08%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TD5A Company Deck
TD5A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial momentum—record shipments and sales, meaningful margin expansion, positive cash generation, a strengthened balance sheet, international go‑direct progress, and multiple product and integration milestones (Android Mobi, pregnancy clearance, FreeStyle Libre 3+ and G7 compatibility, Mobi Tubeless filing). Management acknowledged manageable near‑term headwinds from infusion set supplier shortages and the early operational friction of the PayGo pharmacy transition, plus some international timing and one‑time effects. Overall, the positive results, clear roadmap for product launches, and reaffirmed FY guidance outweigh the disclosed challenges.View all DE:TD5A earnings summariesTD5A Revenue Breakdown
74.21% U.S.
25.79% International

TD5A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€26.77
▲(57.47% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---











